FCPA ROUNDUP: Being In China Corruption Eye Risks Double-Exposure In U.S.
This article was originally published in PharmAsia News
Executive Summary
PharmAsiaNews highlights U.S. Foreign Corrupt Practices Act risks of drug and device makers reaching corruption settlements In China, particularly in Eli Lilly's case, with links to explanations of the issues involved in the law.